Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)

Carrieri, M. P.; Vilotitch, Antoine; Salmon‐Céron, Dominique; Spire, Bruno; Dabis, François; Group, for the ANRS CO HEPAVIH Study; Salmon, Dominique; Sogni, Philippe; Izopet, Jacques; Paradis, Valérie; Carrieri, Patrizia; Poizot‐Martin, Isabelle; Lascoux-Combe, Caroline; Meyer, Laurence; Boufassa, Faroudy; Autran, Brigitte; Roque, A.M.; Solas, Caroline; Fontaine, Hélène; Serfaty, Lawrence; Chêne, Geneviève; Costagliola, Dominique; Couffin‐Cadiergues, Sandrine; Mehawej, H.; Terris, Benoı̂t; Makhlouf, Z.; Dubost, G.; Tessier, Frédéric J.; Gibault, Laure; Beuvon, Frédéric; Chambon, E.; Lazure, T.; Krivine, Anne; Katlama, Christine; Valantin, Marc Antoine; Stitou, Hind; Benhamou, Yves; Charlotte, F.; Fourati, Slim; Simón, Ainhoa; Cacoub, P.; Nafissa, S.; Zaegel, O.; Ménard, Amélie; Geneau, P.; Tamalet, Catherine; Pialoux, Gilles; Bonnard, Philippe; Bani‐Sadr, Firouzé; Slama, Laurence; L’Yavanc, Thomas; Callard, P; Bendjaballah, F.; Lependeven, Catherine; Marchou, B.; Alric, Laurent; Barange, Karl; Métivier, Sophie; Fooladi, Abbas Ali Imani; Rosenthal, Éric; Durant, J.; Haudebourg, Juliette; Saint-Paul, M; Bouchaud, Olivier; Ziol, Marianne; Baazia, Y.; Uzan, Marc; Bicart‐See, A.; Garipuy, D.; Ferro-Collados, M. J.; Selves, J.; Nicot, Florence; Yéni, Patrick; Gervais, Anne; Adle‐Biassette, Homa; Molina, Jean Michel; Combe, Christian; Bertheau, Philippe; Duclos, J M; Palmer, P.; Girard, P; Lacombe, Karine; Campa, Pauline; Wendum, Dominique; Cervera, Pascale; Adam, Jamila K.; Harchi, N.; Delfraissy, Jean François; Goujard, Cécile; Quertainmont, Yann; Pallier, C.; Vittecoq, D.; Lortholary, Olivier; Duvivier, Claudine; Shoai‐Tehrani, Michka; Néau, Didier; Morlat, Philippe; Lacaze-Buzy, L; Caldato, S.; Bioulac‐Sage, Paulette; Trimoulet, P.; Reigadas, Sandrine; Zucman, David; Majerholc, C.; Guitard, F.; Boué, François; Devoto, J. Polo; Kansau, Imad; Chambrin, Véronique; Pignon, C.; Berroukeche, L.; Fior, R; Martinez, Valérie; Deback, Claire; Lévy, Yves; Dominguez, Stéphanie; Lelièvre, Jean Daniel; Lascaux, Anne-Sophie; Melica, Giovanna; Raffi, François; Billaud, Éric; Alavena, C.; Rodallec, Audrey; Peyramond, D.; Chidiac, Christian; Miailhes, Patrick; Ader, Florence; Biron, F.; Boibieux, A.; Cotte, Laurent; Ferry, Tristan; Perpoint, Thomas; Koffi, J.; Zoulim, Fabien; Bailly, François; Lack, Philippe; Maynard, Michaela; Radenne, Sylvie; Amiri, Mehdi; Beniken, D.; Ritleng, A S; Azar, Madona; Honoré, Patrick M.; Breau, S.; Joulié, A.; Mole, M. Leonard; Bolliot, Claudine; Chouraqui, F.; Touam, F.; André, Fiona; Ouabdesselam, N.; Partouche, C.; Alexandre, Guy P.; Ganon, Amandine; Champetier, Antoine; Hüe, H.; Brosseau, Delphine; Brochier, C.; Thoirain, Valérie; Rannou, M.; Bornarel, Dominique; Gillet, S.; Delaune, Jean; Pambrun, Élodie; Dequae-Merchadou, Laurence; Frosch, Anne E.; Maradan, Gwenaëlle; Cheminat, O.; Marcellin, Fabienne; Mora, Marion; Protopopescu, Camélia; Roux, Perrine; Lions, C.; Loko, Marc-Arthur; Winnock, María

doi:10.1093/cid/civ217

Cited by 21 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This figure is in line with results from a previous study on the same cohort, which showed a protective effect of cannabis use on insulin resistance . Other studies in the general population found similar results regarding cannabis use and insulin resistance .…”

Section: Discussionsupporting

confidence: 92%

“…Spontaneous HCV clearers could also be included (second enrolment phase). Further information about the ANRS CO13‐HEPAVIH cohort design is available elsewhere . The cohort received approval from the Comité de Protection des Personnes Ile‐de‐France III (Institutional Review Board).…”

Section: Methodsmentioning

confidence: 99%

“…Further information about the ANRS CO13-HEPAVIH cohort design is available elsewhere. 24,29 The cohort received approval from the All authors had access to the study data and reviewed and approved the final manuscript.…”

Section: Design Of the Cohort And Settingmentioning

confidence: 99%

“…23 Recently, a longitudinal analysis highlighted the protective effect of cannabis use on insulin resistance in HIV-HCV-co-infected patients in the ANRS CO13 HEPAVIH cohort. 24 Previous studies showed the impact of cannabis use on fasting insulin levels and more specifically the lower risk of insulin resistance in the general population. 25,26 As there is a causal link between insulin resistance and steatosis, 27,28 we hypothesized that cannabis use and steatosis are associated.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

Nordmann

Vilotitch

Roux

et al. 2017

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

Liver steatosis is common in human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-co-infected patients. Some recent studies have found that cannabis use is negatively associated with insulin resistance in the general population and in HIV-HCV-co-infected patients. Given the causal link between insulin resistance and steatosis, we hypothesized that cannabis use has a positive impact on steatosis. Therefore, we aimed to study whether cannabis use in this population was associated with a reduced risk of steatosis, measured by ultrasound examination. ANRS CO13-HEPAVIH is a French nationwide multicentre cohort of HIV-HCV-co-infected patients. Medical and socio-behavioural data from clinical follow-up visits and annual self-administered questionnaires were prospectively collected. A cross-sectional analysis was conducted using data from the first visit where both ultrasound examination data for steatosis (positive or negative diagnosis) and data on cannabis use were available. A logistic regression model was used to evaluate the association between cannabis use and steatosis. Among study sample patients (n = 838), 40.1% had steatosis. Fourteen per cent reported daily cannabis use, 11.7% regular use and 74.7% no use or occasional use ("never or sometimes"). Daily cannabis use was independently associated with a reduced prevalence of steatosis (adjusted odds ratio [95% CI] = 0.64 [0.42;0.99]; P = .046), after adjusting for body mass index, hazardous alcohol consumption and current or lifetime use of lamivudine/zidovudine. Daily cannabis use may be a protective factor against steatosis in HIV-HCV-co-infected patients. These findings confirm the need for a clinical evaluation of cannabis-based pharmacotherapies in this population. Eudract.ema.europa.eu number, DGS050367.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Methodsmentioning

confidence: 99%

Section: Design Of the Cohort And Settingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

Nordmann

Vilotitch

Roux

et al. 2017

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast, others showed no effect of smoked marijuana on hepatitis C virus (HCV) progression in patients with human immunodeficiency virus (HIV) . Moreover, cannabis use was associated with less insulin resistance in HIV‐HCV‐coinfected patients . Thus, more research is required to elucidate the role of ECs in CLD, because ECs might exert positive as well as negative effects, indicating a note of caution in the use of these nonspecifically targeted molecules and their modulators (endocannabinoid‐degrading enzymes inhibitors) or exogenous phytocannabinoids as therapeutics for the treatment of CLD.…”

Section: Ecs In Cldmentioning

confidence: 99%